New study tracks pregnancy safety for elafibranor users

NCT ID NCT07556913

Not yet recruiting Knowledge-focused Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated May 08, 2026 · Updated 2 times

Summary

This study watches over people who took elafibranor shortly before or during pregnancy. It aims to see if the drug affects the baby's health or causes birth defects. No extra tests or treatments are given—only routine medical records are reviewed. The study will last about 10 years and follow infants for up to 2 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.